Study: Anti-NGF drug could be effective treatment for OA patients

04/16/2013 | InternalMedicineNews.com (free registration)

Treatment of osteoarthritis of the hip with tanezumab, an anti-nerve growth factor, was found to significantly improve pain and physical function after 16 weeks, according to results from a Phase III study of 621 patients with painful hip OA. According to the study, tanezumab could be useful in treating OA patients who can't tolerate or don't respond to nonopioid treatments.

View Full Article in:

InternalMedicineNews.com (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
European Sales Manager
SentreHEART, Inc.
Germany, Benelux, UK
REG AFFAIRS PROJ MGR - 1400000A7F
Abbott
San Jose, CA
SPECIALIST II SYSTEMS INTEGRATION - 140000033P
Abbott
Dallas, TX
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD